For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Where to buy · live market data

Who's worth your money for Tesamorelin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 35 scored sellers

$3.40/mg

$67.99 · 20mg · 99.8% purity

13 COAs
Buy code MERIT · 10% off

Best value after code

$0.15/mg effective with 15% code

$0.17/mg

$1.20 · 6.98mg · 98.5% purity

6 COAs
Buy code MERIT · 15% off

Most tested

13 independent COAs on file

$14.38/mg

$115 · 8mg · 99.7% purity

13 COAs
Buy code MERIT · 15% off

Average price

$7.59/mg

Sellers

89

45-day trend

-18.2%

78 of 89 sellers have a current price· 35 stale hidden· 8 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tesamorelin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tesamorelin

CAS

218949-48-5

Molecular formula

C221H366N72O67S

Sequence

YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL

Typical dose range

2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC

Half-life

~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)

Independent evidence

COAs for Tesamorelin

314 third-party tests across 52 vendors. Each card links to the full report.

All 314 COAs for Tesamorelin →
Measured purity 79.8%–100.0% across 192 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.95 %
Aug 2026
Janoshik Analytical Limited

For

Tesamorelin

by Longeva· batch PM-260719-TESAMORELIN-01

Aggregated · 3rd-party listing
99.31 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by Virtus Peptides· batch NS-20260601 | TSM10-WHITE

Aggregated · 3rd-party listing
99.86 %
Jul 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 160-310X-DK

Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM-13

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Optima Supply· batch OS-2026-1763

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Hydro Research Peptides· batch HR-2026-4509

✓ Vendor-published
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by optimasupply.is· batch OS-2026-1763

COA on file
Aggregated · 3rd-party listing
79.84 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Nova Peptides· batch NV-P-G8YE

Aggregated · 3rd-party listing
99.97 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch tsm20-04

Aggregated · 3rd-party listing
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Profound Aminos· batch Black Cap

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

Tesamorelin

by OROS Research· batch OR-LPTES10-626-B2

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

Tesamorelin

by Nova Peptides· batch NV-P-IPPF

✓ Vendor-published
99.83 %
Jun 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch TES202607

COA on file
Aggregated · 3rd-party listing
99.89 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10-06022026

Aggregated · 3rd-party listing
99.81 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 136-02-SM-WT

Aggregated · 3rd-party listing
99.04 %
Jun 2026
Accumark Labs

For

Tesamorelin

by Polaris Peptides· batch POL-TESA10-9

Aggregated · 3rd-party listing
99.37 %
Jun 2026
Horizon Analytical

For

Tesamorelin

by Blank Peptides· batch B-3699671-P

Aggregated · 3rd-party listing
99.40 %
Jun 2026
Prime Analytical Laboratories, LLC

For

Tesamorelin

by Soma Peptides· batch TEX062641

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

Tesamorelin

by OROS Research· batch OR-LPTES5-626-B7

Aggregated · 3rd-party listing
99.54 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Rescue Research USA· batch WP-TS-2606

✓ Vendor-published
99.95 %
Jun 2026
MZ Biolabs Moderate

For

Tesamorelin

by Sports Technology Labs· batch 2-1576-30

COA on file
Aggregated · 3rd-party listing
99.78 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10.05.28.26

Aggregated · 3rd-party listing
99.26 %
Jun 2026
Janoshik Analytical Limited

For

Tesamorelin

by Verified Peptides· batch TM07261020J

✓ Vendor-published
99.89 %
Jun 2026
ILS Laboratories

For

Tesa

by Ion Peptide· batch TSM10-06022026

COA on file
Research depth

23 citations indexed for Tesamorelin

All research on Tesamorelin →

Study · 2026

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol

Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

meta-analysis · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

meta-analysis · 2026

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis

BackgroundHIV-associated lipodystrophy, a complication of combined antiretroviral therapy (CART), causes significant physical and psychological distress in people living with HIV (PLWH), compromising treatment adherence.